Lessons learned from biosimilar epoetins and insulins

British Journal of Diabetes and Vascular Disease

Volumn 10, Issue 2, 2010, Pages 90-97

  Kuhlmann, Martin ^a   Marre, Michel ^b  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Biosimilars; EMEA; Epoetin; Eprex; Insulin; Marvel; Pure red cell aplasia

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR PROTEIN; FOLLOW ON BIOLOGIC; GENERIC DRUG; HEMOGLOBIN A1C; HUMAN INSULIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G ANTIBODY; INSULIN; INSULIN ANTIBODY; INSULIN GLARGINE; ISOPHANE INSULIN; NEUTRAL INSULIN; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ASSAY; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPURITY; DRUG MANUFACTURE; DRUG SAFETY; DRUG STORAGE; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRACTICE GUIDELINE; PREFILLED SYRINGE; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; PURE RED CELL ANEMIA; REVIEW; SIDE EFFECT; SYRINGE; UNSPECIFIED SIDE EFFECT;

EID: 77952509288     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651409355454     Document Type: Review

References (41)

1. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006;11:341-346
2. Schellekens H, Ryff JC. 'Biogenerics': the off-patent biotech products. Trends Pharmacol Sci 2002;23:119-121
3. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006;21(suppl 5):v13-v6.
4. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(suppl 5):v4-8.
5. European Medicines Agency. International Conference on Harmonization Topic Q6B: Specifications: test procedures and acceptance criteria for biotechnological/biological products. Document # CPMP/ICH/365/96. September 1999. London: EMEA, 1999. www.emea.europa.eu/pdfs/human/ich/036596en.pdf. (Accessed 2 September 2009)
6. Wiecek A, Mikhail A. European regulatory guidelines for biosimilars. Nephrol Dial Transplant 2006;21(suppl 5):v17-20.
7. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. London: EMEA, 2005. www.emea.europa.eu/pdfs/ human/biosimilar/043704en.pdf. (Accessed 13 April 2009)
8. Committee for Medicinal Products for Human Use. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London: EMEA, 2006. www.emea.europa.eu/pdfs/ human/biosimilar/4934805en.pdf. (Accessed 13 April 2009)
9. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: EMEA, 2006. www.emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf. (Accessed 13 April 2009)
10. Committee for Medicinal Products for Human Use. Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant human insulin. London: EMEA, 2006. www.emea.europa.eu/pdfs/human/biosimilar/3277505en.pdf. (Accessed 13 April 2009)
11. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietins. London, 22 March 2006. Document ref EMEA/CHMP/BMWP/94526/2005 Corr. London: EMEA, 2006. www.emea.europa.eu/ pdfs/human/biosimilar/9452605en.pdf. (Accessed 1 May 2009)
12. European Medicines Agency. International Conference on Harmonization Topic Q7: Good manufacturing practice for active pharmaceutical ingredients. Document #CPMP/ICH/4106/00. November 20, 2000. London: EMEA, 2000. www.emea.europa.eu/pdfs/human/iclV410600en.pdf. (Accessed 2 September 2009)
13. European Medicines Agency. International Conference on Harmonization Topic Q5A (R1): Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Document #CPMP/ICH/295/95. October 1997. London: EMEA, 1997. www.emea.europa.eu/pdfs/human/ich/029595en.pdf. (Accessed 2 September 2009)
14. Walsh G. Therapeutic insulins and their large-scale manufacture. Appl Microbiol Biotechnol 2005;67:151-159
15. Joshi SR, Parikh RM, Das AK. Insulin: history, biochemistry, physiology and pharmacology. J Assoc Physicians India 2007;55(suppl):19-25.
16. European Medicines Agency. Pre-authorisation Evaluation of Medicines for Human Use. Withdrawal Assessment Report for Insulin Human Rapid Marvel. 21 February 2008. London: EMEA, 2008. Document reference EMEA/CHMP/317778/2007. www.emea.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/31777807en.pdf. (Accessed 1 May 2009).
17. European Medicines Agency. Pre-authorisation Evaluation of Medicines for Human Use. Withdrawal Assessment Report for Insulin Human Long Marvel. 21 February 2008. London: EMEA, 2008. Document reference EMEA/CHMP/70349/2008. www.emea.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/7034908en.pdf. (Accessed 1 May 2009)
18. European Medicines Agency. Pre-authorisation Evaluation of Medicines for Human Use. Withdrawal Assessment Report for Insulin Human 30/70 Mixed Marvel. 21 February 2008. London: EMEA, 2008. Document reference EMEA/CHMP/70179/2008. www.emea.europa.eu/humandocs/PDFs/EPAR/insulinhumanrapidmarvel/701790en.pdf. (Accessed 1 May 2009)
19. European Medicines Agency. Press release: Marvel LifeSciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel. 16 January 2008. London: EMEA, 2008. EMEA/2435/2008.
20. Wang FF, Kung CKH, Goldwasser E. Some chemical properties of human erythropoietin. Endocrinology 1985;116:2286-2292
21. Lai PH, Everett R, Wang FF. Structural characterization of human erythropoietin. J Biol Chem 1986;261:3116-3121
22. Macdougall IC. Present and future strategies in the treatment of renal anemia. Nephrol Dial Transplant 2001;16(suppl 5):50-55
23. Cheer SM, Wagstaff AJ. Epoetin beta: a review of its clinical use in the treatment of anemia in patients with cancer. Drugs 2004;64:323-346
24. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-276
25. Elliott S, Egrie J, Browne J et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 2004;32:1146-1155
26. Celik E, Calik P, Halloran SM, Oliver SG. Production of recombinant human erythropoietin from Pichia pastors and its structural analysis. J Appl Microbiol 2007;103:2084-2094
27. Ratner M. Pharma swept up in biogenerics gold rush. Nat Biotechnol 2009;27:299-301.
28. Ramos AS, Schmidt CA, Andrade SS et al. Biological evaluation of recombinant human erythropoietin in pharmaceutical products. Braz J Med Biol Res 2003;36:1561-1569
29. Schellekens H. Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant 2005;20(suppl 4):iv31-6.
30. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004;3:8-12.
31. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antieryth-ropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475 (Pubitemid 34441737)
32. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18:473-480 (Pubitemid 40425360)
33. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia "epidemic" - mystery completely revealed? Perit Dial Int 2007;27(suppl 2):S303-07.
34. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle- associated protein in epoetin formulations: a risk factor for immuno- genicity? Pharm Res 2003:20:1903-1907
35. Sharma B, Bader F, Templeman T et al. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex. Eur J Hospital Pharm 2004;5:86-91.
36. Ryan MH, Heavner GA, Brigham-Burke M et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol 2006;6:647-655
37. Johnson and Johnson Pharmaceutical Research and Development. Summary of PRCA case reports: update on the actions by Johnson and Johnson Pharmaceutical Research and Development regarding erythropoietin antibody-positive pure red cell aplasia. Raritan: Johnson and Johnson Pharmaceutical Research and Development, 2005.
38. Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Practice & Research. Clin Haematol 2005;18:381-387
39. Roger SD, Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther 2008:33:459-464
40. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21(suppl 5):v9-12.
41. Covic A, Cannataq-Andia J, Cancarini G et al. Biosimilars and biophar-maceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008;23:3731-3737